How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group?

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group?

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario